EcoDrugPlus

Protein Kinase Camp-Activated Catalytic Subunit Alpha

Ensembl ID : ENSUPAG00010011860
Gene Symbol: PRKACA
1 Cross references
283 Possible Orthologues:

Protein Kinase Camp-Activated Catalytic Subunit Beta

Ensembl ID : ENSUPAG00010011454
Gene Symbol: PRKACB
1 Cross references
297 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSUPAG00010003246
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSUPAG00010012626
Gene Symbol: PPP3CA
1 Cross references
230 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSUPAG00010006311
Gene Symbol: PTK2
3 Cross references
326 Possible Orthologues:

Protein Tyrosine Kinase 6

Ensembl ID : ENSUPAG00010004618
Gene Symbol: PTK6
1 Cross references
170 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSUPAG00010008763
Gene Symbol: PTPN11
3 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSUPAG00010023420
Gene Symbol: PTPRB
1 Cross references
264 Possible Orthologues:

Purine Nucleoside Phosphorylase

Ensembl ID : ENSUPAG00010007985
Gene Symbol: PNP
1 Cross references
428 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSUPAG00010000073
Gene Symbol: P2RX3
3 Cross references
270 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSUPAG00010006202
Gene Symbol: P2RX7
3 Cross references
187 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSUPAG00010006704
Gene Symbol: P2RY1
1 Cross references
190 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).